News >

Acquired HER2 Mutations Cause Endocrine Resistance in ER+ Breast Cancer

Jason M. Broderick @jasoncology
Published: Thursday, Mar 15, 2018

Elaine R. Mardis, PhD

Elaine R. Mardis, PhD
Acquired HER2 mutations cause endocrine resistance in some patients with ER+/HER2-negative breast cancer, according to findings reported during a media preview for the 2018 AACR Annual Meeting.

= .0064). The median PFS was 8.3 months for the lapatinib/AI arm.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication